Biogen Abandons Aduhelm, Pivots to Other Alzheimers Therapies

In a significant setback, Biogen, a prominent pharmaceutical company, has announced the discontinuation of its Alzheimer's treatment, Aduhelm. The drug, once hailed as a potential breakthrough, faced numerous challenges following its launch a few years ago. Biogen's decision marks a shift in focus towards other treatment options for this debilitating disease.

Representative image

A Promising Start and Subsequent Struggles

Aduhelm garnered significant attention as the first new Alzheimer's drug to be introduced in nearly two decades. The Food and Drug Administration (FDA) granted accelerated approval for the drug in 2021, but it required an additional study before considering full approval. However, the drug's efficacy and safety concerns emerged, leading to hesitation among doctors and limited coverage by insurers. The federal government's Medicare program also imposed strict restrictions on who could receive Aduhelm, further limiting its reach.

Financial Implications and Strategic Shift

The challenges faced by Aduhelm had a significant impact on Biogen's financial performance. Initially priced at USD 56,000 per year, analysts had predicted substantial revenue generation for the company. However, weak evidence supporting the drug's effectiveness and limited market access resulted in disappointing sales figures. In response, Biogen announced a significant reduction in Aduhelm's marketing efforts in 2022.

Recognizing the challenges and potential advancements in the field, Biogen conducted a review of its research and development program. The company concluded that the time and investment required for the additional study, coupled with the likelihood of advancements in Alzheimer's treatment, made continuing Aduhelm's development unviable. As a result, Biogen decided to discontinue the Aduhelm program and book a charge of approximately USD 60 million in its fourth-quarter financial results.

Shifting Focus and Collaborations

Despite the setback with Aduhelm, Biogen remains committed to addressing Alzheimer's disease. The company is redirecting its efforts towards other promising treatment options and collaborating with Eisai, a Japanese drugmaker, to market Leqembi, another Alzheimer's treatment that has received full FDA approval. Leqembi has demonstrated modest but significant effectiveness in slowing cognitive decline associated with Alzheimer's disease.

Stock Market Reaction

News of Biogen's decision to discontinue Aduhelm was met with a positive response in the stock market. Shares of Biogen Inc., based in Cambridge, Massachusetts, climbed by more than USD 4 to USD 251.72 on Wednesday morning, while the broader Standard & Poor's 500 index experienced a slight decline.

Biogen's decision to discontinue Aduhelm marks a significant development in the ongoing fight against Alzheimer's disease. While the drug initially sparked hope, its challenges highlight the complexities of developing effective treatments for this devastating condition. Biogen's strategic shift towards other treatment options and collaborations reflects the company's commitment to addressing the unmet needs of Alzheimer's patients and their families.